ClinicalTrials.gg
CompletedNCT03915860Updated Dec 15, 2021Results posted

Participant Reported Outcomes With Use of Trifarotene 50 μg/g Cream in the Treatment of Moderate Facial and Truncal Acne Vulgaris

A Phase 3 interventional study of Trifarotene in Acne Vulgaris, sponsored by Galderma R&D. Completed at 9 sites in United States. Open to participants aged 9 Years and older. Per ClinicalTrials.gov, last updated 2021-12-15.

Sponsored by Galderma R&D (part of Galderma Group AG) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
47
Allocation
Not applicable
Ages
9 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies testing trifarotene in Acne Vulgaris — none open to participants now, 1 under way, 1 of them phase 3. trifarotene · Acne Vulgaris.

Enrollment
12th of 12
47 · median 507
Started
2019
the only one that year
Phase 3
6 of 12
none open now
Registered
5th of 12
by date
Lead sponsor
9 of 12
Galderma R&D

Among the 12 studies testing trifarotene in Acne Vulgaris, this one is the 12th largest by enrollment, is the only one that started in 2019, is one of 6 in phase 3, and was the 5th registered.

Acne Vulgaris

791 studies on the registry are indexed under Acne Vulgaris; 93 are open to participants now.

Browse Acne Vulgaris studies →

Open to participants now

None of the 12 studies testing trifarotene in Acne Vulgaris is open now. The open studies under Acne Vulgaris, anywhere →

About trifarotene

trifarotene: first FDA approval 2019 (AKLIEF). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 46 Acne Vulgaris studies recruiting now, 16 (35%) set no upper age limit and 29 (63%) stop at 75 or younger; 21 take children under 18; 17 take healthy volunteers.

This study: 9 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 12 studies testing trifarotene in Acne Vulgaris as a file.
02

Study summary

Participant Reported Outcomes with use of Trifarotene 50 μg/g Cream in participants with Moderate Facial and Truncal Acne Vulgaris

Read the detailed description

There was no formal hypothesis to be tested. Approximately 50 subjects would be enrolled to evaluate the subject reported outcomes (quality of life and satisfaction survey). The sample size was not based on any formal hypothesis testing.

03

Conditions studied

  • Acne Vulgaris

Browse trials for

04

Who can participate

Ages eligible
9 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The participant was a male or female, 9 years of age or older, at Screening visit.
  • The participant had moderate acne at Screening and Baseline.
  • The participant was a female of non .
  • The participant was a female of childbearing potential with a negative pregnancy test and who was strictly abstinent or who agreed to use an effective and approved method for the duration of the study and at least 1 months after the last study drug application.

Exclusion criteria

Exclusion Criteria:

  • The participant had severe forms of acne (e.g., acne conglobate, acne fulminant) or secondary acne form (e.g., chloracne, drug induced acne, etc.).
  • The participant had any uncontrolled or serious disease or any medical or surgical condition that may either interfere with the interpretation of the trial results and/or put the participant at significant risk (according to the Investigator's judgment) if the participant took part to the trial.
  • The participant had been exposed to excessive ultraviolet (UV) radiation within one month prior to the Baseline visit or the participant was planning intense UV exposure during the study (i.ed, occupational exposure to the sun, sunbathing, tanning salon use, phototherapy, etc.).
  • The participant was unwilling to refrain from use of prohibited medication during the Clinical Trial.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
47 participants (actual)

Study arms

  • Experimental
    Trifarotene

    Participants applied Trifarotene 50 μg/g topically once daily in the evening for 24 weeks.

    Drug: Trifarotene

Interventions

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Dermatology Life Quality Index (DLQI) Total Score at Week 12 and 24

    The DLQI was validated 10-item questionnaire for participants aged \>16 years that measured the dermatology-related limitations of functional ability and the frequency, severity, and impact of general inflammatory skin conditions on the quality-of-life (QOL). The total DLQI score was calculated by summing the scores of each question, resulting in a maximum of 30 and a minimum of 0. Responses to each questions were assessed on a scale of 0 to 3, where 0 is "not at all" and 3 is "very much". Scores from all 10 questions added up to give total DLQI scores ranged from 0 (not at all) to 30 (very much), higher scores indicated more impact on quality of life.

    Time frame: Baseline, Week 12 and Week 24

  2. Change From Baseline in C-DLQI (Children's Dermatology Life Quality Index) Score at Week 12 and 24

    The C-DLQI are validated 10-item questionnaire for participants aged \<=16 that measured the dermatology related limitations of functional ability and the frequency, severity, and impact of general inflammatory skin conditions on the quality-of-life (QOL). Questions were scored as follows: No effect (0-1), Small effect (2-6), Moderate effect (7-12), Very large effect (13-18), Extremely large effect (19-30). The total C-DLQI score was calculated by summing the scores of each question, resulting in a maximum of 30 (Extremely large effect) and a minimum of 0 (No effect). A lower score on the C-DLQI indicates increased QOL.

    Time frame: Baseline, Week 12 and Week 24

  3. Change From Baseline in Comprehensive Quality of Life (QOL) Measure for Facial and Truncal Acne (CompAQ) Total Score at Week 12, 24

    The CompAQ questionnaire is a comprehensive measure of facial and truncal acne's impact on health-related QOL. The 20 questions consisted of 5 domains that assessed a variety of psychosocial and physical impacts of acne: Psychological/Emotional, Social (Judgement from Others), Social Interactions, Treatment Concerns, Physical Symptoms. Each question is assessed with a numeric score between 0 (Never) and 8 (All the time) with a total possible score range of 0 (No effect) -160 (greater adverse impact). The higher the score, the more quality of life is impaired.

    Time frame: Baseline, Week 12 and Week 24

  4. Number of Participants With Satisfaction Questionnaire - Treatment Area Face at Week 12 and 24/End of Treatment (ET)

    Participants Satisfaction Questionnaire included questions: a) How bothered were you by treatment side effects? : Not bothered at all, Bothered somewhat, Bothered, Bothered a great deal b) Satisfied with the time it took for treatment to work: Very satisfied, Satisfied, Somewhat satisfied, Not satisfied c) How satisfied were you with the effectiveness of the treatment? Very satisfied, Satisfied, Somewhat satisfied, Not satisfied d) How do you feel about yourself, since starting your treatment?: Very much better, A lot better, A little better, Worse. e) Overall, are you satisfied with the treatment? : Very satisfied, Satisfied, Somewhat satisfied, Not satisfied. f) Would you consider using this treatment again: Yes, No. g) Did you use the provided moisturizing lotion?: Yes, No.

    Time frame: Week 12 and Week 24/End of Treatment (ET)

  5. Number of Participants With Satisfaction Questionnaire - Treatment Area Trunk at Week 12 and 24/ End of Treatment (ET)

    Participants Satisfaction Questionnaire included questions: a) How bothered were you by treatment side effects? : Not bothered at all, Bothered somewhat, Bothered, Bothered a great deal b) Satisfied with the time it took for treatment to work: Very satisfied, Satisfied, Somewhat satisfied, Not satisfied c) How satisfied were you with the effectiveness of the treatment? Very satisfied, Satisfied, Somewhat satisfied, Not satisfied d) How do you feel about yourself, since starting your treatment?: Very much better, A lot better, A little better, Worse. e) Overall, are you satisfied with the treatment? : Very satisfied, Satisfied, Somewhat satisfied, Not satisfied. f) Would you consider using this treatment again: Yes, No. g) Did you use the provided moisturizing lotion?: Yes, No.

    Time frame: Week 12 and Week 24/ET

  6. Change From Baseline in EQ-5D-5L Index Score at Week 12 and 24

    EQ-5D-5L is a 2-part measurement. The first part is comprised of the following 5 participant-reported dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. The responses are used to derive the health state index scores using the United States (US) algorithm, with scores ranging from -0.109 (extreme problems) to 1 (no problems). A higher score indicates better health state.

    Time frame: Baseline, Week 12 and Week 24

  7. Change From Baseline in EQ-5D-5L VAS at Week 12 and 24

    The EQ-5D-5L assesses general health-related quality of life. The second portion of the scale is a self-perceived health score assessed using a VAS that ranges from 0 (the worst imaginable health) to 100 (the best imaginable health), with higher scores indicating higher health utility.

    Time frame: Baseline, Week 12 and Week 24

Secondary outcomes

  1. Percentage of Participants Who Achieved an IGA Score of 1 (Almost Clear) or 0 (Clear) and At Least a 2-Grade Improvement From Baseline to Week 12 and Week 24

    IGA was an assessment scale used to evaluate facial acne severity. IGA was recorded from components collected on the case report form (CRF) using a 5-point scale where (0 = clear; 1 = almost clear; 2 = mild; 3 = moderate; 4 = severe) based on inflammation, pustules and papulation/infiltration. Success Rate was defined as the percentage of participants who achieved an IGA score of 1 (Almost Clear) or 0 (Clear) and at least a 2-grade improvement from Baseline to Week 12 and Week 24.

    Time frame: Baseline, Week 12 and Week 24

  2. Percentage of Participants With Physician's Global Assessment of Truncal Acne Success Rate at Week 12 and 24

    The Physician's Global Assessment (PGA) was an instrument to evaluate the truncal acne severity in the shoulders, upper back and upper anterior chest areas. PGA was recorded from components collected on the CRF using a 5-point scale where (0 = clear; 1 = almost clear; 2 = mild; 3 = moderate; 4 = severe) based on inflammation, pustules and papulation/infiltration. Success Rate was defined as the percentage of participants who achieved an PGA score of 1 (Almost Clear) or 0 (Clear) and at least a 2-grade improvement from Baseline to Week 12 and Week 24. All missing values were imputed by LOCF.

    Time frame: Week 12 and 24

  3. Percent Change From Baseline in Facial Inflammatory and Non-inflammatory Lesion Count at Week 12 and 24

    Percent change from Baseline was calculated as the values at Week 12 (and 24) minus the value at Baseline divided by Baseline value \* 100. All missing values were imputed by LOCF.

    Time frame: Baseline, Week 12 and 24

  4. Percent Change From Baseline in Trunk Inflammatory and Non-inflammatory Lesion Count at Week 12 and 24

    Percent change from Baseline was calculated as the values at Week 12 (and 24) minus the value at Baseline divided by Baseline value \* 100. All missing values were imputed by LOCF.

    Time frame: Baseline, Week 12 and Week 24

07

Results

Posted Dec 15, 2021
Limitations and caveats
Small sample size (no formal sample size calculation).

Participant flow

The study was conducted at United States between 27 March 2019 and 23 December 2019.

Participant flow — Overall Study
MilestoneTrifarotene
Started47
Treated46
Completed33
Not completed14
Withdrew: Adverse event3
Withdrew: Withdrawal by subject6
Withdrew: Lost to follow-up2
Withdrew: Other than specified3

Outcome measures

PrimaryChange From Baseline in Dermatology Life Quality Index (DLQI) Total Score at Week 12 and 24

The DLQI was validated 10-item questionnaire for participants aged \>16 years that measured the dermatology-related limitations of functional ability and the frequency, severity, and impact of general inflammatory skin conditions on the quality-of-life (QOL). The total DLQI score was calculated by summing the scores of each question, resulting in a maximum of 30 and a minimum of 0. Responses to each questions were assessed on a scale of 0 to 3, where 0 is "not at all" and 3 is "very much". Scores from all 10 questions added up to give total DLQI scores ranged from 0 (not at all) to 30 (very much), higher scores indicated more impact on quality of life.

Time frame:
Baseline, Week 12 and Week 24
Reported as:
Mean · score on a scale
Change From Baseline in Dermatology Life Quality Index (DLQI) Total Score at Week 12 and 24
score on a scaleTrifarotene
Week 12-1.8 ± 2.97
Week 24-0.5 ± 5.85
PrimaryChange From Baseline in C-DLQI (Children's Dermatology Life Quality Index) Score at Week 12 and 24

The C-DLQI are validated 10-item questionnaire for participants aged \<=16 that measured the dermatology related limitations of functional ability and the frequency, severity, and impact of general inflammatory skin conditions on the quality-of-life (QOL). Questions were scored as follows: No effect (0-1), Small effect (2-6), Moderate effect (7-12), Very large effect (13-18), Extremely large effect (19-30). The total C-DLQI score was calculated by summing the scores of each question, resulting in a maximum of 30 (Extremely large effect) and a minimum of 0 (No effect). A lower score on the C-DLQI indicates increased QOL.

Time frame:
Baseline, Week 12 and Week 24
Reported as:
Mean · score on a scale
Change From Baseline in C-DLQI (Children's Dermatology Life Quality Index) Score at Week 12 and 24
score on a scaleTrifarotene
Week 12-1.7 ± 4.28
Week 24-1.2 ± 5.03
PrimaryChange From Baseline in Comprehensive Quality of Life (QOL) Measure for Facial and Truncal Acne (CompAQ) Total Score at Week 12, 24

The CompAQ questionnaire is a comprehensive measure of facial and truncal acne's impact on health-related QOL. The 20 questions consisted of 5 domains that assessed a variety of psychosocial and physical impacts of acne: Psychological/Emotional, Social (Judgement from Others), Social Interactions, Treatment Concerns, Physical Symptoms. Each question is assessed with a numeric score between 0 (Never) and 8 (All the time) with a total possible score range of 0 (No effect) -160 (greater adverse impact). The higher the score, the more quality of life is impaired.

Time frame:
Baseline, Week 12 and Week 24
Reported as:
Mean · score on a scale
Change From Baseline in Comprehensive Quality of Life (QOL) Measure for Facial and Truncal Acne (CompAQ) Total Score at Week 12, 24
score on a scaleTrifarotene
Week 12-7.4 ± 17.39
Week 24-0.6 ± 39.96
PrimaryNumber of Participants With Satisfaction Questionnaire - Treatment Area Face at Week 12 and 24/End of Treatment (ET)

Participants Satisfaction Questionnaire included questions: a) How bothered were you by treatment side effects? : Not bothered at all, Bothered somewhat, Bothered, Bothered a great deal b) Satisfied with the time it took for treatment to work: Very satisfied, Satisfied, Somewhat satisfied, Not satisfied c) How satisfied were you with the effectiveness of the treatment? Very satisfied, Satisfied, Somewhat satisfied, Not satisfied d) How do you feel about yourself, since starting your treatment?: Very much better, A lot better, A little better, Worse. e) Overall, are you satisfied with the treatment? : Very satisfied, Satisfied, Somewhat satisfied, Not satisfied. f) Would you consider using this treatment again: Yes, No. g) Did you use the provided moisturizing lotion?: Yes, No.

Time frame:
Week 12 and Week 24/End of Treatment (ET)
Reported as:
Count of participants · Participants
Number of Participants With Satisfaction Questionnaire - Treatment Area Face at Week 12 and 24/End of Treatment (ET)
ParticipantsTrifarotene
Week 12: Bothered By Treatment Side Effects: Not bothered at all18
Week 12: Bothered By Treatment Side Effects: Bothered somewhat15
Week 12: Bothered By Treatment Side Effects: Bothered0
Week 12: Bothered By Treatment Side Effects: Bothered a great deal1
Week 12: Satisfied with the time it took for treatment to work: Very satisfied8
Week 12: Satisfied with the time it took for treatment to work: satisfied14
Week 12: Satisfied with the time it took for treatment to work: Somewhat satisfied9
Week 12: Satisfied with the time it took for treatment to work: Not satisfied3
Week 12: Satisfied with effectiveness of treatment: Very satisfied5
Week 12: Satisfied with effectiveness of treatment: satisfied18
Week 12: Satisfied with effectiveness of treatment: Somewhat satisfied8
Week 12: Satisfied with effectiveness of treatment: Not satisfied3
Week 12: Feel about yourself: Very much better5
Week 12: Feel about yourself: A lot better14
Week 12: Feel about yourself: A little better13
Week 12: Feel about yourself: Worse2
Week 12: Overall-satisfied with the treatment: Very satisfied6
Week 12: Overall-satisfied with the treatment: satisfied18
Week 12: Overall-satisfied with the treatment: Somewhat satisfied7
Week 12: Overall-satisfied with the treatment: Not satisfied3
Week 12: Would you consider using this treatment again -Yes31
Week 12: Would you consider using this treatment again - No3
Week 12: Used moisturizing lotion: Yes32
Week 12: Used moisturizing lotion: No2
Week 12: Used moisturizing lotion: moisturizer helps to reduce irritation: Yes23
Week 12: Used moisturizing lotion: moisturizer helps to reduce irritation: No9
Week 12: Used moisturizing lotion: moisturizer helps you to be adherent to study treatment: Yes7
Week 12: Used moisturizing lotion: moisturizer helps you to be adherent to study treatment: No25
Week 12: Used moisturizing lotion: moisturizer was pleasant to use: Yes15
Week 12: Used moisturizing lotion: moisturizer was pleasant to use: No17
Week 12: Used moisturizing lotion: None of the above: Yes2
Week 12: Used moisturizing lotion: None of the above: No30
Week 24/ET: Bothered By Treatment Side Effects: Not bothered at all22
Week 24/ET: Bothered By Treatment Side Effects: Bothered somewhat13
Week 24/ET: Bothered By Treatment Side Effects: Bothered4
Week 24/ET: Bothered By Treatment Side Effects: Bothered a great deal0
Week 24/ET: Satisfied with the time it took for treatment to work: Very satisfied9
Week 24/ET: Satisfied with the time it took for treatment to work: satisfied20
Week 24/ET: Satisfied with the time it took for treatment to work: Somewhat satisfied5
Week 24/ET: Satisfied with the time it took for treatment to work: Not satisfied5
Week 24/ET: Satisfied with effectiveness of treatment: Very satisfied11
Week 24/ET: Satisfied with effectiveness of treatment: satisfied15
Week 24/ET: Satisfied with effectiveness of treatment: Somewhat satisfied8
Week 24/ET: Satisfied with effectiveness of treatment: Not satisfied5
Week 24/ET: Feel about yourself: Very much better9
Week 24/ET: Feel about yourself: A lot better9
Week 24/ET: Feel about yourself: A little better19
Week 24/ET: Feel about yourself: Worse2
Week 24/ET: Overall-satisfied with the treatment: Very satisfied12
Week 24/ET: Overall-satisfied with the treatment: satisfied12
Week 24/ET: Overall-satisfied with the treatment: Somewhat satisfied11
Week 24/ET: Overall-satisfied with the treatment: Not satisfied4
Week 24/ET: Would you consider using this treatment again -Yes28
Week 24/ET: Would you consider using this treatment again - No11
Week 24/ET: Used moisturizing lotion: Yes38
Week 24/ET: Used moisturizing lotion: No1
Week 24/ET: Used moisturizing lotion: moisturizer helps to reduce irritation: Yes30
Week 24/ET: Used moisturizing lotion: moisturizer helps to reduce irritation: No8
Week 24/ET: Used moisturizing lotion: moisturizer helps you to be adherent to study treatment: Yes7
Week 24/ET: Used moisturizing lotion: moisturizer helps you to be adherent to study treatment: No31
Week 24/ET: Used moisturizing lotion: moisturizer was pleasant to use: Yes15
Week 24/ET: Used moisturizing lotion: moisturizer was pleasant to use: No23
Week 24/ET: Used moisturizing lotion: None of the above: Yes2
Week 24/ET: Used moisturizing lotion: None of the above: No36
PrimaryNumber of Participants With Satisfaction Questionnaire - Treatment Area Trunk at Week 12 and 24/ End of Treatment (ET)

Participants Satisfaction Questionnaire included questions: a) How bothered were you by treatment side effects? : Not bothered at all, Bothered somewhat, Bothered, Bothered a great deal b) Satisfied with the time it took for treatment to work: Very satisfied, Satisfied, Somewhat satisfied, Not satisfied c) How satisfied were you with the effectiveness of the treatment? Very satisfied, Satisfied, Somewhat satisfied, Not satisfied d) How do you feel about yourself, since starting your treatment?: Very much better, A lot better, A little better, Worse. e) Overall, are you satisfied with the treatment? : Very satisfied, Satisfied, Somewhat satisfied, Not satisfied. f) Would you consider using this treatment again: Yes, No. g) Did you use the provided moisturizing lotion?: Yes, No.

Time frame:
Week 12 and Week 24/ET
Reported as:
Count of participants · Participants
Number of Participants With Satisfaction Questionnaire - Treatment Area Trunk at Week 12 and 24/ End of Treatment (ET)
ParticipantsTrifarotene
Week 12: Bothered By Treatment Side Effects: Not bothered at all23
Week 12: Bothered By Treatment Side Effects: Bothered somewhat9
Week 12: Bothered By Treatment Side Effects: Bothered2
Week 12: Bothered By Treatment Side Effects: Bothered a great deal0
Week 12: Satisfied with the time it took for treatment to work: Very satisfied8
Week 12: Satisfied with the time it took for treatment to work: satisfied16
Week 12: Satisfied with the time it took for treatment to work: Somewhat satisfied8
Week 12: Satisfied with the time it took for treatment to work: Not satisfied2
Week 12: Satisfied with effectiveness of treatment: Very satisfied5
Week 12: Satisfied with effectiveness of treatment: satisfied18
Week 12: Satisfied with effectiveness of treatment: Somewhat satisfied10
Week 12: Satisfied with effectiveness of treatment: Not satisfied1
Week 12: Feel about yourself: Very much better6
Week 12: Feel about yourself: A lot better14
Week 12: Feel about yourself: A little better14
Week 12: Feel about yourself: Worse0
Week 12: Overall-satisfied with the treatment: Very satisfied8
Week 12: Overall-satisfied with the treatment: satisfied13
Week 12: Overall-satisfied with the treatment: Somewhat satisfied10
Week 12: Overall-satisfied with the treatment: Not satisfied3
Week 12: Would you consider using this treatment again -Yes32
Week 12: Would you consider using this treatment again - No2
Week 12: Used moisturizing lotion: Yes33
Week 12: Used moisturizing lotion: No1
Week 12: Used moisturizing lotion: moisturizer helps to reduce irritation: Yes23
Week 12: Used moisturizing lotion: moisturizer helps to reduce irritation: No10
Week 12: Used moisturizing lotion: moisturizer helps you to be adherent to study treatment: Yes8
Week 12: Used moisturizing lotion: moisturizer helps you to be adherent to study treatment: No25
Week 12: Used moisturizing lotion: moisturizer was pleasant to use: Yes14
Week 12: Used moisturizing lotion: moisturizer was pleasant to use: No19
Week 12: Used moisturizing lotion: None of the above: Yes3
Week 12: Used moisturizing lotion: None of the above: No30
Week 24/ET: Bothered By Treatment Side Effects: Not bothered at all22
Week 24/ET: Bothered By Treatment Side Effects: Bothered somewhat13
Week 24/ET: Bothered By Treatment Side Effects: Bothered4
Week 24/ET: Bothered By Treatment Side Effects: Bothered a great deal0
Week 24/ET: Satisfied with the time it took for treatment to work: Very satisfied7
Week 24/ET: Satisfied with the time it took for treatment to work: satisfied22
Week 24/ET: Satisfied with the time it took for treatment to work: Somewhat satisfied5
Week 24/ET: Satisfied with the time it took for treatment to work: Not satisfied5
Week 24/ET: Satisfied with effectiveness of treatment: Very satisfied8
Week 24/ET: Satisfied with effectiveness of treatment: satisfied19
Week 24/ET: Satisfied with effectiveness of treatment: Somewhat satisfied7
Week 24/ET: Satisfied with effectiveness of treatment: Not satisfied5
Week 24/ET: Feel about yourself: Very much better8
Week 24/ET: Feel about yourself: A lot better11
Week 24/ET: Feel about yourself: A little better19
Week 24/ET: Feel about yourself: Worse1
Week 24/ET: Overall-satisfied with the treatment: Very satisfied10
Week 24/ET: Overall-satisfied with the treatment: satisfied17
Week 24/ET: Overall-satisfied with the treatment: Somewhat satisfied9
Week 24/ET: Overall-satisfied with the treatment: Not satisfied3
Week 24/ET: Would you consider using this treatment again -Yes28
Week 24/ET: Would you consider using this treatment again - No11
Week 24/ET: Used moisturizing lotion: Yes37
Week 24/ET: Used moisturizing lotion: No2
Week 24/ET: Used moisturizing lotion: moisturizer helps to reduce irritation: Yes30
Week 24/ET: Used moisturizing lotion: moisturizer helps to reduce irritation: No7
Week 24/ET: Used moisturizing lotion: moisturizer helps you to be adherent to study treatment: Yes8
Week 24/ET: Used moisturizing lotion: moisturizer helps you to be adherent to study treatment: No29
Week 24/ET: Used moisturizing lotion: moisturizer was pleasant to use: Yes13
Week 24/ET: Used moisturizing lotion: moisturizer was pleasant to use: No24
Week 24/ET: Used moisturizing lotion: None of the above: Yes2
Week 24/ET: Used moisturizing lotion: None of the above: No35
PrimaryChange From Baseline in EQ-5D-5L Index Score at Week 12 and 24

EQ-5D-5L is a 2-part measurement. The first part is comprised of the following 5 participant-reported dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. The responses are used to derive the health state index scores using the United States (US) algorithm, with scores ranging from -0.109 (extreme problems) to 1 (no problems). A higher score indicates better health state.

Time frame:
Baseline, Week 12 and Week 24
Reported as:
Mean · score on a scale
Change From Baseline in EQ-5D-5L Index Score at Week 12 and 24
score on a scaleTrifarotene
Week 12-0.0140 ± 0.09626
Week 240.0135 ± 0.08394
PrimaryChange From Baseline in EQ-5D-5L VAS at Week 12 and 24

The EQ-5D-5L assesses general health-related quality of life. The second portion of the scale is a self-perceived health score assessed using a VAS that ranges from 0 (the worst imaginable health) to 100 (the best imaginable health), with higher scores indicating higher health utility.

Time frame:
Baseline, Week 12 and Week 24
Reported as:
Mean · score on a scale
Change From Baseline in EQ-5D-5L VAS at Week 12 and 24
score on a scaleTrifarotene
Week 121.0 ± 8.96
Week 243.7 ± 7.96
SecondaryPercentage of Participants Who Achieved an IGA Score of 1 (Almost Clear) or 0 (Clear) and At Least a 2-Grade Improvement From Baseline to Week 12 and Week 24

IGA was an assessment scale used to evaluate facial acne severity. IGA was recorded from components collected on the case report form (CRF) using a 5-point scale where (0 = clear; 1 = almost clear; 2 = mild; 3 = moderate; 4 = severe) based on inflammation, pustules and papulation/infiltration. Success Rate was defined as the percentage of participants who achieved an IGA score of 1 (Almost Clear) or 0 (Clear) and at least a 2-grade improvement from Baseline to Week 12 and Week 24.

Time frame:
Baseline, Week 12 and Week 24
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved an IGA Score of 1 (Almost Clear) or 0 (Clear) and At Least a 2-Grade Improvement From Baseline to Week 12 and Week 24
percentage of participantsTrifarotene
Week 126.4 (1.3 to 17.5)
Week 2419.1 (9.1 to 33.3)
SecondaryPercentage of Participants With Physician's Global Assessment of Truncal Acne Success Rate at Week 12 and 24

The Physician's Global Assessment (PGA) was an instrument to evaluate the truncal acne severity in the shoulders, upper back and upper anterior chest areas. PGA was recorded from components collected on the CRF using a 5-point scale where (0 = clear; 1 = almost clear; 2 = mild; 3 = moderate; 4 = severe) based on inflammation, pustules and papulation/infiltration. Success Rate was defined as the percentage of participants who achieved an PGA score of 1 (Almost Clear) or 0 (Clear) and at least a 2-grade improvement from Baseline to Week 12 and Week 24. All missing values were imputed by LOCF.

Time frame:
Week 12 and 24
Reported as:
Number · percentage of participants
Percentage of Participants With Physician's Global Assessment of Truncal Acne Success Rate at Week 12 and 24
percentage of participantsTrifarotene
Week 1214.9 (6.2 to 28.3)
Week 246.4 (1.3 to 17.5)
SecondaryPercent Change From Baseline in Facial Inflammatory and Non-inflammatory Lesion Count at Week 12 and 24

Percent change from Baseline was calculated as the values at Week 12 (and 24) minus the value at Baseline divided by Baseline value \* 100. All missing values were imputed by LOCF.

Time frame:
Baseline, Week 12 and 24
Reported as:
Mean · percent change
Percent Change From Baseline in Facial Inflammatory and Non-inflammatory Lesion Count at Week 12 and 24
percent changeTrifarotene
Inflammatory Lesion: Week 12-35.81 ± 41.124
Inflammatory Lesion: Week 24-38.59 ± 42.643
Non-Inflammatory Lesion: Week 12-23.17 ± 45.506
Non-Inflammatory Lesion: Week 24-35.16 ± 46.946
SecondaryPercent Change From Baseline in Trunk Inflammatory and Non-inflammatory Lesion Count at Week 12 and 24

Percent change from Baseline was calculated as the values at Week 12 (and 24) minus the value at Baseline divided by Baseline value \* 100. All missing values were imputed by LOCF.

Time frame:
Baseline, Week 12 and Week 24
Reported as:
Mean · percent change
Percent Change From Baseline in Trunk Inflammatory and Non-inflammatory Lesion Count at Week 12 and 24
percent changeTrifarotene
Inflammatory Lesion: Week 12-39.97 ± 32.564
Inflammatory Lesion: Week 24-41.36 ± 39.131
Non-Inflammatory Lesion: Week 12-35.24 ± 39.337
Non-Inflammatory Lesion: Week 24-44.20 ± 37.650

Adverse events

Collected over From start of the study drug administration up to end of the study (Week 24).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Trifarotene0/46 (0%)0/46 (0%)9/46 (19.6%)
Most frequent other events
Most frequent other events
EventTrifarotene
Application site painGeneral disorders5/46
Application site dermatitisGeneral disorders3/46
SunburnInjury, poisoning and procedural complications3/46

Baseline characteristics

Analysis was performed on Intent to treat (ITT) population that included all enrolled participants.

Age, Continuous
Age, Continuous(years)Trifarotene
Mean15.6 ± 3.00
Sex: Female, Male
Sex: Female, Male(Participants)Trifarotene
Female13
Male34
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Trifarotene
Hispanic or Latino10
Not Hispanic or Latino37
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Trifarotene
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American5
White42
More than one race0
Unknown or Not Reported0
Dermatology Life Quality Index (DLQI) Score at Baseline
Dermatology Life Quality Index (DLQI) Score at Baseline(score on a scale)Trifarotene
Mean2.8 ± 3.00
C-DLQI (Children's Dermatology Life Quality Index) Score at Baseline
C-DLQI (Children's Dermatology Life Quality Index) Score at Baseline(score on a scale)Trifarotene
Mean3.2 ± 4.17
Comprehensive Quality of Life (QOL) Measure for Facial and Truncal Acne at Baseline
Comprehensive Quality of Life (QOL) Measure for Facial and Truncal Acne at Baseline(score on a scale)Trifarotene
Mean37.8 ± 17.69
EuroQoL 5-Dimension (EQ-5D-5L) Index Score at Baseline
EuroQoL 5-Dimension (EQ-5D-5L) Index Score at Baseline(score on a scale)Trifarotene
Mean0.9416 ± 0.07334

1 further baseline measures are reported on the registry.

08

Study locations

9 sites
  • Galderma Investigational Site
    Fort Smith, Arkansas 72916, United States
  • Galderma Investigational Site
    Beverly, Massachusetts 01915, United States
  • Galderma Investigational Site
    Portsmouth, New Hampshire 03801, United States
  • Galderma Investigational Site
    Philadelphia, Pennsylvania 19103, United States
  • Galderma Investigational Site
    Austin, Texas 78759, United States
  • Galderma Investigational Site
    Beaumont, Texas 77701, United States
  • Galderma Investigational Site
    Irving, Texas 75062, United States
  • Galderma Investigational Site
    Pflugerville, Texas 78660, United States
  • Galderma Investigational Site
    Richardson, Texas 75081, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2019 to primary completion in Dec 2019, 8 months.

Results were first posted in Dec 2021, 1 year 11 months after primary completion.

Of 53 industry-sponsored phase 3 interventional studies under Acne Vulgaris, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 17. This study's 8 months is below that.

Counting every sponsor, half of 62 studies reached it within 13 months; a quarter within 10 and three quarters within 17.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 12, 2019
First posted
Apr 16, 2019
StartActual
Mar 27, 2019
Primary completionActual
Dec 23, 2019
CompletionActual
Dec 23, 2019
Results first posted
Dec 15, 2021
Last update
Dec 15, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 15, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03915860
Lead sponsor
Galderma R&D
Responsible party
Sponsor
First posted
Apr 16, 2019
Start date
Mar 27, 2019
Primary completion
Dec 23, 2019
Completion
Dec 23, 2019
Results posted
Dec 15, 2021
Last update
Dec 15, 2021

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Trifarotene

Start the discussion